相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sustained anti-osteoporotic action of risedronate compared to anti-RANKL antibody following discontinuation in ovariectomized mice
Toshinobu Omiya et al.
BONE REPORTS (2020)
Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women
A. Fassio et al.
BONE (2019)
Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis
Hennie G. Raterman et al.
DRUGS (2019)
Fracture risk following intermission of osteoporosis therapy
E. M. Dennison et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
Steven R. Cummings et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Insights into the bisphosphonate holiday: a preliminary FTIRI study
A. L. Boskey et al.
OSTEOPOROSIS INTERNATIONAL (2018)
The effects of estrogen deficiency on cortical bone microporosity and mineralization
Divya Sharma et al.
BONE (2018)
Bisphosphonate Drug Holiday and Fracture Risk: A Population-Based Cohort Study
Annette L. Adams et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance
Ashley A. Lloyd et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Protective effect of low-dose risedronate against osteocyte apoptosis and bone loss in ovariectomized rats
Tingjun Ye et al.
PLOS ONE (2017)
Osteocyte Apoptosis Caused by Hindlimb Unloading is Required to Trigger Osteocyte RANKL Production and Subsequent Resorption of Cortical and Trabecular Bone in Mice Femurs
Pamela Cabahug-Zuckerman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
Pannexin-1 and P2X7-Receptor Are Required for Apoptotic Osteocytes in Fatigued Bone to Trigger RANKL Production in Neighboring Bystander Osteocytes
Wing Yee Cheung et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
Alendronate treatment alters bone tissues at multiple structural levels in healthy canine cortical bone
Claire Acevedo et al.
BONE (2015)
Inhibition of Osteocyte Apoptosis Prevents the Increase in Osteocytic Receptor Activator of Nuclear Factor κB Ligand (RANKL) but Does Not Stop Bone Resorption or the Loss of Bone Induced by Unloading
Lilian I. Plotkin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties
N. Hassler et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Osteocyte apoptosis is required for production of osteoclastogenic signals following bone fatigue in vivo
Oran D. Kennedy et al.
BONE (2014)
3D Assessment of Cortical Bone Porosity and Tissue Mineral Density Using High-Resolution mu CT: Effects of Resolution and Threshold Method
Paolo E. Palacio-Mancheno et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research
Elizabeth Shane et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate
Brian Louis McNabb et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populations
Oran D. Kennedy et al.
BONE (2012)
Influence of Bone Affinity on the Skeletal Distribution of Fluorescently Labeled Bisphosphonates In Vivo
Anke J. Roelofs et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures
Eve Donnelly et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice
L. I. Plotkin et al.
BONE (2011)
Novel actions of bisphosphonates in bone: Preservation of osteoblast and osteocyte viability
Teresita Bellido et al.
BONE (2011)
The relationship between the chemistry and biological activity of the bisphosphonates
Frank H. Ebetino et al.
BONE (2011)
Bisphosphonates: The first 40 years
R. Graham G. Russell
BONE (2011)
Effect of Stopping Risedronate after Long-Term Treatment on Bone Turnover
Richard Eastell et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Effects of Estrogen Deficiency and Bisphosphonate Therapy on Osteocyte Viability and Microdamage Accumulation in an Ovine Model of Osteoporosis
Orlaith Brennan et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2011)
Osteocyte apoptosis and control of bone resorption following ovariectomy in mice
K. B. Emerton et al.
BONE (2010)
Morphological Assessment of Basic Multicellular Unit Resorption Parameters in Dogs Shows Additional Mechanisms of Bisphosphonate Effects on Bone
Matthew R. Allen et al.
CALCIFIED TISSUE INTERNATIONAL (2010)
An in vitro Assay to Measure Targeted Drug Delivery to Bone Mineral
Wolfgang Jahnke et al.
CHEMMEDCHEM (2010)
Differences Between Bisphosphonates in Binding Affinities for Hydroxyapatite
M. A. Lawson et al.
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS (2010)
Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group
Ermond van Beek et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Structural requirements for bisphosphonate actions in vitro
Ermond van Beek et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Mineralization Density Distribution of Postmenopausal Osteoporotic Bone Is Restored to Normal After Long-Term Alendronate Treatment: qBEI and sSAXS Data From the Fracture Intervention Trial Long-Term Extension (FLEX)
P. Roschger et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Fluorescent Risedronate Analogues Reveal Bisphosphonate Uptake by Bone Marrow Monocytes and Localization Around Osteocytes In Vivo
Anke J. Roelofs et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery
Wolfgang Jahnke et al.
NATURE CHEMICAL BIOLOGY (2010)
Bone Turnover in Bone Biopsies of Patients with Low-Energy Cortical Fractures Receiving Bisphosphonates: A Case Series
Reina Armamento-Villareal et al.
CALCIFIED TISSUE INTERNATIONAL (2009)
Osteocyte Apoptosis Controls Activation of Intracortical Resorption in Response to Bone Fatigue
Luis Cardoso et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Thermodynamics of Bisphosphonates Binding to Human Bone: A Two-Site Model
Sujoy Mukherjee et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2009)
Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study
B. A. Lenart et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Spectroscopic markers of bone quality in alendronate-treated postmenopausal women
A. L. Boskey et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
Paul D. Miller et al.
BONE (2008)
Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment
Matthew R. Allen et al.
CALCIFIED TISSUE INTERNATIONAL (2008)
Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats
Robyn K. Fuchs et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: Time-dependent inhibition of human farnesyl pyrophosphate synthase
James E. Dunford et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment
Matthew R. Allen et al.
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2008)
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
R. G. G. Russell et al.
OSTEOPOROSIS INTERNATIONAL (2008)
A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: Prevalence, risk factors, and clinical characteristics
Michael Pazianas et al.
CLINICAL THERAPEUTICS (2007)
Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading
Helene Follet et al.
BONE (2007)
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial
Dennis M. Black et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate
Matthew R. Allen et al.
BONE (2006)
The molecular mechanism of nitrogen-containing bisphosphonates as anti osteoporosis drugs
Kathryn L. Kavanagh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite
G. H. Nancollas et al.
BONE (2006)
Genetic background influences cortical bone response to ovariectomy
CY Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
High-dose risedronate treatment partially preserves cancellous bone mass and microarchitecture during long-term disuse
CY Li et al.
BONE (2005)
Mice with a disruption of the thrombospondin 3 gene differ in geometric and biomechanical properties of bone and have accelerated development of the femoral head
KD Hankenson et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Effects of risedronate on trabecular microstructure and biomechanical properties in ovariectomized rat tibia
M Ito et al.
OSTEOPOROSIS INTERNATIONAL (2005)
Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Intervention Trial long-term extension
KE Ensrud et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases
SL Ruggiero et al.
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2004)
Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra
S Komatsubara et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage
J Li et al.
CALCIFIED TISSUE INTERNATIONAL (2001)
Bone brittleness varies with genetic background in A/J and C57BL/6J inbred mice
KJ Jepsen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2001)
Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women
P Roschger et al.
BONE (2001)
Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles
T Mashiba et al.
BONE (2001)
Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib
T Mashiba et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women
GY Boivin et al.
BONE (2000)
分享论文
